Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of ¹⁸F-DCFPyL PET/CT with Comparison to Multiparametric MRI.

ABSTRACT: Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (¹⁸F-DCFPyL) may improve detection of recurrence compared with multiparametric MRI; however, histopathologic validation is lacking. Purpose To determine the sensitivity, specificity, and positive predictive value (PPV) of ¹⁸F-DCFPyL PET/CT based on histologic analysis and to compare with pelvic multiparametric MRI in men with biochemically recurrent prostate cancer. Materials and Methods Men were prospectively recruited after prostatectomy and/or radiation therapy with risi

SUBMITTER: Lindenberg L 

PROVIDER: S-EPMC7457947 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature